Copyright
©The Author(s) 2016.
World J Diabetes. Dec 15, 2016; 7(20): 572-598
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Figure 12 Significantly greater 5% and 10% weight loss achieved following 3 mg subcutaneous liraglutide compared to placebo and orlistat.
Five percent and 10% responder rates in NCT00480909 reported at 1 year (see text).
- Citation: Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598
- URL: https://www.wjgnet.com/1948-9358/full/v7/i20/572.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i20.572